Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Race to Erase MS Forum and Expo
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Idebenone for primary progressive multiple sclerosis
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Patient reported outcome measures in neurogenic bladder.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Biogen Idec receives negative opinion from the CHMP on Fampyra
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Biogen Reports Another Tecfidera PML Case
Vitamin D intake and incidence of multiple sclerosis.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Daclizumab (anti-CD25) in multiple sclerosis.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Fingolimod is a potential novel therapy for multiple sclerosis.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

Pages